TFMB- (R) -2-HG

TFMB- (R) -2-HG is a cell membrane-permeable (R) -2-HG and acute myeloid leukemia (AML) oncogenic factor. TFMB- (R) -2-HG competitively inhibits α-ketoglutarate-dependent dioxygenases such as KDM2B and FTO. TFMB- (R) -2-HG impairs cell differentiation in response to Estrogen withdrawal. TFMB- (R) -2-HG is used in acute myeloid leukemia and glioma research[1][2][3].

Product Specifications

CAS Number

[1445700-01-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Estrogen Receptor/ERR; Fat Mass and Obesity-associated Protein (FTO) ; Histone Demethylase

Type

Reference compound

Related Pathways

Epigenetics; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tfmb-r-2-hg.html

Concentration

10mM

Purity

98.26

Solubility

DMSO : 233.33 mg/mL (ultrasonic)

Smiles

O=C([C@@H](CC1)OC1=O)OCC2=CC=CC(C(F)(F)F)=C2

Molecular Formula

C13H11F3O4

Molecular Weight

288.22

Precautions

H302, H315, H319, H335

References & Citations

[1]Losman JA, et al. (R) -2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013 Mar 29;339 (6127) :1621-5.|[2]Philip B, et al. Mutant IDH1 Promotes Glioma Formation In Vivo. Cell Rep. 2018 May 1;23 (5) :1553-1564.|[3]Gunn K, et al. (R) -2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers. Cancer Discov. 2023 Jun 2;13 (6) :1478-1497.